Physician profile
Sarah Stone
NPI 1972921682
$2,490.22
in general payments reported to CMS, 2019-2025
17 companies · $654 in 2025
The $654 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,465 · 2022: $188 · 2023: $183 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $1,465.08 | 2019 | |
| Argenx US, INC. | $370.70 | 2022-2023 | Vyvgart, Vyvgart Hytrulo |
| Genentech, INC. | $129.62 | 2025 | Ocrevus |
| Lilly USA, LLC | $113.85 | 2025 | Kisunla |
| Acadia Pharmaceuticals INC | $63.91 | 2025 | Nuplazid |
| Abbvie INC. | $51.60 | 2025 | |
| Alexion Pharmaceuticals, INC. | $50.18 | 2025 | Ultomiris |
| Pfizer INC. | $44.47 | 2025 | |
| Janssen Biotech, INC. | $30.50 | 2025 | |
| Genentech USA, INC. | $29.77 | 2025 | Ocrevus Zunovo |
| Lundbeck LLC | $25.83 | 2025 | Vyepti |
| Tanabe Pharma America, INC. | $23.44 | 2025 | Radicava |
| Neurocrine Biosciences, INC. | $21.41 | 2025 | |
| Neurelis, INC. | $21.03 | 2025 | Valtoco |
| Tg Therapeutics, INC. | $19.26 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $15.50 | 2025 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $14.07 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.